HAC (Russian)
RSCI (Russian)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services


Download full text PDF

Professor E. Onuchina (1), MD; S. Brikova (2); Yu. Belikova (2); S. Gontarenko (2) 1 -Irkutsk State Medical Academy of Postgraduate Education 2 -War Veterans Hospital, Irkutsk

The incidence of complicated gastroesophageal reflux disease is more than 2.5-fold higher in elderly people. The age factor is of the greatest importance for mucosal ulceration in the distal esophagus. The proton pump inhibitor (PPI)alginate (Gaviscon®) combination is a more pathogenetically sound treatment than PPI monotherapy.

gastroesophageal reflux disease
elderly age
sodium alginate
Gaviscon-double action®

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

  1. Onuchina E.V., Brikova S.I., Tsukanov V.V. Ispol'zovanie preparata Geviskon dlja kupirovanija simptomatiki pischevodnyh, vnepischevodnyh sindromov i funktsional'noj dispepsii u bol'nyh GERB pozhilogo i starcheskogo vozrasta // Eksperim. i klin. gastroenterol. – 2010; 10: 80–6.
  2. Onuchina E.V. Klinicheskie projavlenija, faktory riska i effektiv nost' lechenija gastroezofageal'noj refljuksnoj bolezni u lits pozhilogo vozrasta. Avtoref. dis. …d-ra med. nauk. Krasnojarsk, 2011; s. 45.
  3. Ang, D., Sifrim D., Tack J. Mechanisms of heartburn // Nat. Clin. Pract. Gastroenterol. Hepatol. – 2008; 5: 383–92.
  4. Corley D., Kubo A., Levin T. et al. Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994–2006 // Gut. – 2009; 58: 182–8.
  5. Farr5. é R., Fornari F., Blondeau K. et al. Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus // Gut. – 2010; 59: 164–9.
  6. Kwiatek M., Roman S., Fareeduddin A. et al. An alginate-antacid formulation 6. (Gaviscon Double Action Liquid) can eliminate or displace the postprandial 'acid pocket' in symptomatic GERD patients // Aliment. Pharmacol. Ther. – 2011; 34: 59–66.
  7. Lien H., Chang C., Yeh H. et al. Increasing prevalence of erosive esophagitis 7. among Taiwanese aged 40 years and above: a comparison between two time periods // J. Clin. Gastroenterol. – 2009; 43: 926–32.
  8. Lundell L., Dent J., Bennet J. Endoscopic assessment of oesophagitis 8. clinical and fuctional correlates and futher validation of Los Angeles classification // Gut. – 1999; 45: 72–180.
  9. Murray L., Watson P., Johnston B. et al. Risk of adenocarcinoma in Barrett's 9. oesophagus: population based study // BMJ. – 2003; 327: 534–5.
  10. Salvioli G., Tambara E., Gaetti E. et al. Chemico-physical property and bile 10. acid binding capacity of several antacids // Minerva Dietol/Gastroenterol. – 1989; 35: 79–83.
  11. Savarino E., de Bortoli N., Zentilin P. et al. Alginate controls hearburn in 11. patients with erosive and nonerosive reflux disease // World J. Gastroenterol. – 2012; 18: 4371–8.
  12. Spechler S., Sharma P., Souza R. et al. American Gastroenterological 12. Association technical review on the management of Barrett's esophagus // Gastroenterology. – 2011; 140: 18–52.
  13. Strugala V., Avis J., Jolliffe I.G. et al. The role of an alginate suspension on 13. pepsin and bile acids – key aggressors in the gastric refluxate. Does this have implications for the treatment of gastro-oesophageal reflux disease? // J. Pharm. Pharmacol. – 2009; 61: 1021–8.
  14. Vakil N., van Zanten S., Kahrilas P. et al. The Monreal Definition and 14. Classification of gastroesophageal reflux disease: a global evidence-based consensus // Am. J. Gastroenterology. – 2006; 101: 1900–20.
  15. Zerbib F., Roman S., Ropert A., et al. Esophageal pH-impedance monitoring 15. and symptom analysis in GERD: a study in patients off and on therapy // Am. J. Gastroenterol. – 2006; 101: 1956–63.
  16. Hampson F. et al. Alginate rafts and their characterization // Int. J. Pharm. – 16. 2005; 294 (1–2): 137–47.COMPLICATIONS OF GAST